About: Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.74 (-2.29%)
TPST NASDAQ Tempest Therapeutics Inc
Tempest Therapeutics Inc share price
TPST price activity
Last Price
$0.740
Change (24hr)
-0.02 USD (-2.29%)
Volume
161.47K
Volume (4w avg)
-
Open
$0.76
Day Range
$0.74 - $0.81
Previous Close
$0.76
Last Trade
12 Oct, 8:30 pm GMT+0
Delayed
12 Oct, 8:30 pm GMT+0
TPST price performance
Delayed
12 Oct, 8:30 pm GMT+0
TPST Market Signals